Investor Toolkit
| Investor Overview
| Emergent BioSolutions Inc. is a leading biopharmaceutical company dedicated to one simple mission—to protect life. We develop, manufacture and commercialize immune related biologics, vaccines and biotherapeutics that assist the body’s immune system to prevent or treat infectious and other life threatening diseases. Our marketed product, BioThrax® (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. Our product pipeline also includes: two “next generation” anthrax vaccines, two anthrax therapeutics (immunoglobulin and monoclonal), two botulinum vaccines and a botulinum therapeutic, an oral typhoid vaccine, a next generation tuberculosis vaccine, a hepatitis B immunotherapy, and a chlamydia vaccine.
| | |
 |
Annual Reports
A copy of the company’s Form 10-K, including the company’s completed audited financial statements, for the year ended December 31, 2007, filed with the Securities and Exchange Commission, is available without charge, upon written request to Investor Relations, Emergent BioSolutions Inc., Suite 400, Rockville, MD 20850.
|
| There are currently no events scheduled. |
| Primary IR Contact | Robert G. Burrows
Vice President,
Investor Relations
Emergent BioSolutions Inc.
Phone: (301) 795-1877
E-mail: burrowsr@ebsi.com |
| | | Transfer Agent | American Stock Transfer
& Trust Company
59 Maiden Lane
New York, NY 10038
Phone: (212) 936-5100
Website: http://www.amstock.com |
|
Receive Email Alerts | | Sign up to receive Email alerts whenever Emergent BioSolutions Inc. posts new information to the site. Just enter your Email address and click Submit. |
|
|
Safe Harbor Statement
|
| The documents contained in (or directly accessible from) this website include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, including our expected revenue growth and net earnings for 2008, and any other statements containing the words “believes”, “expects”, “anticipates”, “plans”, “estimates” and similar expressions, are forward-looking statements. There are a number of important factors that could cause the company’s actual results to differ materially from those indicated by such forward-looking statements, including the timing of, and our ability to obtain and maintain, regulatory approval for FluBlok; our plans for future manufacture and sale of FluBlok; our ability to obtain new BioThrax sales contracts with the U.S. government; our plans for future sales of BioThrax; our plans to pursue label expansions and improvements for BioThrax; our plans to expand our manufacturing facilities and capabilities; the rate and degree of market acceptance and clinical utility of our products; our ongoing and planned development programs, preclinical studies and clinical trials; our ability to identify and acquire or in license products and product candidates that satisfy our selection criteria; the potential benefits of our existing collaboration agreements and our ability to enter into selective additional collaboration arrangements; the timing of and our ability to obtain and maintain regulatory approvals for our other product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our intellectual property portfolio; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the company’s current report on Form 10-Q for the quarter ended March 31, 2008 and subsequent reports filed with the SEC. The company disclaims any intention or obligation to update any forward-looking statements contained in or directly accessible from documents on this website.
|
|
|
|
RSS Feeds
|
More >>
